Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 109

1.

Tumor mutational load predicts survival after immunotherapy across multiple cancer types.

Samstein RM, Lee CH, Shoushtari AN, Hellmann MD, Shen R, Janjigian YY, Barron DA, Zehir A, Jordan EJ, Omuro A, Kaley TJ, Kendall SM, Motzer RJ, Hakimi AA, Voss MH, Russo P, Rosenberg J, Iyer G, Bochner BH, Bajorin DF, Al-Ahmadie HA, Chaft JE, Rudin CM, Riely GJ, Baxi S, Ho AL, Wong RJ, Pfister DG, Wolchok JD, Barker CA, Gutin PH, Brennan CW, Tabar V, Mellinghoff IK, DeAngelis LM, Ariyan CE, Lee N, Tap WD, Gounder MM, D'Angelo SP, Saltz L, Stadler ZK, Scher HI, Baselga J, Razavi P, Klebanoff CA, Yaeger R, Segal NH, Ku GY, DeMatteo RP, Ladanyi M, Rizvi NA, Berger MF, Riaz N, Solit DB, Chan TA, Morris LGT.

Nat Genet. 2019 Feb;51(2):202-206. doi: 10.1038/s41588-018-0312-8. Epub 2019 Jan 14.

PMID:
30643254
2.

Long-term quality of life in older patients with HPV-related oropharyngeal cancer.

Baxi SS, Cullen G, Xiao H, Atoria CL, Sherman EJ, Ho A, Lee NY, Elkin EB, Pfister DG.

Head Neck. 2018 Nov;40(11):2321-2328. doi: 10.1002/hed.25159. Epub 2018 Nov 13.

PMID:
30421835
3.

Vemurafenib Redifferentiation of BRAF Mutant, RAI-Refractory Thyroid Cancers.

Dunn LA, Sherman EJ, Baxi SS, Tchekmedyian V, Grewal RK, Larson SM, Pentlow KS, Haque S, Tuttle RM, Sabra MM, Fish S, Boucai L, Walters J, Ghossein RA, Seshan VE, Ni A, Li D, Knauf JA, Pfister DG, Fagin JA, Ho AL.

J Clin Endocrinol Metab. 2018 Sep 25. doi: 10.1210/jc.2018-01478. [Epub ahead of print]

PMID:
30256977
4.

NCCN Guidelines Insights: Head and Neck Cancers, Version 1.2018.

Colevas AD, Yom SS, Pfister DG, Spencer S, Adelstein D, Adkins D, Brizel DM, Burtness B, Busse PM, Caudell JJ, Cmelak AJ, Eisele DW, Fenton M, Foote RL, Gilbert J, Gillison ML, Haddad RI, Hicks WL, Hitchcock YJ, Jimeno A, Leizman D, Maghami E, Mell LK, Mittal BB, Pinto HA, Ridge JA, Rocco J, Rodriguez CP, Shah JP, Weber RS, Witek M, Worden F, Zhen W, Burns JL, Darlow SD.

J Natl Compr Canc Netw. 2018 May;16(5):479-490. doi: 10.6004/jnccn.2018.0026.

PMID:
29752322
5.

Patterns of recurrence in oral tongue cancer with perineural invasion.

Cracchiolo JR, Xu B, Migliacci JC, Katabi N, Pfister DG, Lee NY, Patel SG, Ghossein RA, Wong RJ.

Head Neck. 2018 Jun;40(6):1287-1295. doi: 10.1002/hed.25110. Epub 2018 Mar 9.

PMID:
29522275
6.

Challenges and Opportunities for Developing New Therapeutics for Salivary Gland Cancers.

Ho AL, Pfister DG.

J Oncol Pract. 2018 Feb;14(2):109-110. doi: 10.1200/JOP.18.00039. No abstract available.

PMID:
29436304
7.

Use of Larynx-Preservation Strategies in the Treatment of Laryngeal Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.

Forastiere AA, Ismaila N, Lewin JS, Nathan CA, Adelstein DJ, Eisbruch A, Fass G, Fisher SG, Laurie SA, Le QT, O'Malley B, Mendenhall WM, Patel S, Pfister DG, Provenzano AF, Weber R, Weinstein GS, Wolf GT.

J Clin Oncol. 2018 Apr 10;36(11):1143-1169. doi: 10.1200/JCO.2017.75.7385. Epub 2017 Nov 27.

PMID:
29172863
8.

Phase I study of induction chemotherapy with afatinib, ribavirin, and weekly carboplatin and paclitaxel for stage IVA/IVB human papillomavirus-associated oropharyngeal squamous cell cancer.

Dunn LA, Fury MG, Sherman EJ, Ho AA, Katabi N, Haque SS, Pfister DG.

Head Neck. 2018 Feb;40(2):233-241. doi: 10.1002/hed.24938. Epub 2017 Sep 30.

PMID:
28963790
9.

Phase 2 study evaluating the combination of sorafenib and temsirolimus in the treatment of radioactive iodine-refractory thyroid cancer.

Sherman EJ, Dunn LA, Ho AL, Baxi SS, Ghossein RA, Fury MG, Haque S, Sima CS, Cullen G, Fagin JA, Pfister DG.

Cancer. 2017 Nov 1;123(21):4114-4121. doi: 10.1002/cncr.30861. Epub 2017 Jun 29.

10.

NCCN Guidelines Insights: Head and Neck Cancers, Version 2.2017.

Adelstein D, Gillison ML, Pfister DG, Spencer S, Adkins D, Brizel DM, Burtness B, Busse PM, Caudell JJ, Cmelak AJ, Colevas AD, Eisele DW, Fenton M, Foote RL, Gilbert J, Haddad RI, Hicks WL Jr, Hitchcock YJ, Jimeno A, Leizman D, Lydiatt WM, Maghami E, Mell LK, Mittal BB, Pinto HA, Ridge JA, Rocco J, Rodriguez CP, Shah JP, Weber RS, Witek M, Worden F, Yom SS, Zhen W, Burns JL, Darlow SD.

J Natl Compr Canc Netw. 2017 Jun;15(6):761-770. doi: 10.6004/jnccn.2017.0101.

PMID:
28596256
11.

Variation in use of postoperative chemoradiation following surgery for T1 and T2 oropharyngeal squamous cell carcinoma; National Cancer Database.

Roman BR, Baxi SS, Cracchiolo JR, Blackwell TJ, Pfister DG, McBride S, Ganly I, Shah JP, Patel SG, Morris LG, Cohen MA.

J Surg Oncol. 2017 Sep;116(3):351-358. doi: 10.1002/jso.24674. Epub 2017 Jun 1.

12.

Opportunities and Challenges: Human Papillomavirus and Cancer.

Chu CS, Pfister DG.

J Natl Compr Canc Netw. 2017 May;15(5S):726-729.

PMID:
28515256
13.

Frequent IDH2 R172 mutations in undifferentiated and poorly-differentiated sinonasal carcinomas.

Dogan S, Chute DJ, Xu B, Ptashkin RN, Chandramohan R, Casanova-Murphy J, Nafa K, Bishop JA, Chiosea SI, Stelow EB, Ganly I, Pfister DG, Katabi N, Ghossein RA, Berger MF.

J Pathol. 2017 Aug;242(4):400-408. doi: 10.1002/path.4915. Epub 2017 Jun 9.

14.

Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study.

Bauml J, Seiwert TY, Pfister DG, Worden F, Liu SV, Gilbert J, Saba NF, Weiss J, Wirth L, Sukari A, Kang H, Gibson MK, Massarelli E, Powell S, Meister A, Shu X, Cheng JD, Haddad R.

J Clin Oncol. 2017 May 10;35(14):1542-1549. doi: 10.1200/JCO.2016.70.1524. Epub 2017 Mar 22.

15.

Strategy of Using Intratreatment Hypoxia Imaging to Selectively and Safely Guide Radiation Dose De-escalation Concurrent With Chemotherapy for Locoregionally Advanced Human Papillomavirus-Related Oropharyngeal Carcinoma.

Lee N, Schoder H, Beattie B, Lanning R, Riaz N, McBride S, Katabi N, Li D, Yarusi B, Chan S, Mitrani L, Zhang Z, Pfister DG, Sherman E, Baxi S, Boyle J, Morris LG, Ganly I, Wong R, Humm J.

Int J Radiat Oncol Biol Phys. 2016 Sep 1;96(1):9-17. doi: 10.1016/j.ijrobp.2016.04.027. Epub 2016 May 7.

16.

White adipose tissue inflammation and cancer-specific survival in patients with squamous cell carcinoma of the oral tongue.

Iyengar NM, Ghossein RA, Morris LG, Zhou XK, Kochhar A, Morris PG, Pfister DG, Patel SG, Boyle JO, Hudis CA, Dannenberg AJ.

Cancer. 2016 Dec 15;122(24):3794-3802. doi: 10.1002/cncr.30251. Epub 2016 Aug 10.

17.

The Molecular Landscape of Recurrent and Metastatic Head and Neck Cancers: Insights From a Precision Oncology Sequencing Platform.

Morris LG, Chandramohan R, West L, Zehir A, Chakravarty D, Pfister DG, Wong RJ, Lee NY, Sherman EJ, Baxi SS, Ganly I, Singh B, Shah JP, Shaha AR, Boyle JO, Patel SG, Roman BR, Barker CA, McBride SM, Chan TA, Dogan S, Hyman DM, Berger MF, Solit DB, Riaz N, Ho AL.

JAMA Oncol. 2016 Jul 21. doi: 10.1001/jamaoncol.2016.1790. [Epub ahead of print]

18.

Unmet needs for patients with salivary gland cancer.

Dunn LA, Ho AL, Laurie SA, Pfister DG.

Oral Oncol. 2016 Sep;60:142-5. doi: 10.1016/j.oraloncology.2016.06.003. Epub 2016 Jul 1. No abstract available.

PMID:
27377424
19.

Patterns of regional and distant metastasis in esthesioneuroblastoma.

Banuchi VE, Dooley L, Lee NY, Pfister DG, McBride S, Riaz N, Bilsky MH, Ganly I, Shah JP, Kraus DH, Morris LG.

Laryngoscope. 2016 Jul;126(7):1556-61. doi: 10.1002/lary.25862. Epub 2016 Feb 10.

20.

Risk Adjusting Survival Outcomes in Hospitals That Treat Patients With Cancer Without Information on Cancer Stage.

Pfister DG, Rubin DM, Elkin EB, Neill US, Duck E, Radzyner M, Bach PB.

JAMA Oncol. 2015 Dec;1(9):1303-10. doi: 10.1001/jamaoncol.2015.3151. Erratum in: JAMA Oncol. 2015 Dec;1(9):1323.

21.

Head and Neck Cancers, Version 1.2015.

Pfister DG, Spencer S, Brizel DM, Burtness B, Busse PM, Caudell JJ, Cmelak AJ, Colevas AD, Dunphy F, Eisele DW, Foote RL, Gilbert J, Gillison ML, Haddad RI, Haughey BH, Hicks WL Jr, Hitchcock YJ, Jimeno A, Kies MS, Lydiatt WM, Maghami E, McCaffrey T, Mell LK, Mittal BB, Pinto HA, Ridge JA, Rodriguez CP, Samant S, Shah JP, Weber RS, Wolf GT, Worden F, Yom SS, McMillian N, Hughes M.

J Natl Compr Canc Netw. 2015 Jul;13(7):847-55; quiz 856.

22.

Reply to B. O'Sullivan et Al.

Pfister DG, Baxi SS, Dunn LA, Fury MG.

J Clin Oncol. 2015 May 20;33(15):1710. doi: 10.1200/JCO.2014.60.3563. Epub 2015 Mar 30. No abstract available.

PMID:
25823736
23.

Phase II trial of bevacizumab + cetuximab + cisplatin with concurrent intensity-modulated radiation therapy for patients with stage III/IVB head and neck squamous cell carcinoma.

Fury MG, Xiao H, Sherman EJ, Baxi S, Smith-Marrone S, Schupak K, Gewanter R, Gelblum D, Haque S, Schoder H, Shah JP, Katabi N, Kurtzman R, Lipson B, Cox L, Lee NY, Pfister DG.

Head Neck. 2016 Apr;38 Suppl 1:E566-70. doi: 10.1002/hed.24041. Epub 2015 Jul 6.

24.

Evaluating the potential role of PET/CT in the posttreatment surveillance of head and neck cancer.

Baxi SS, Dunn L, Pfister DG.

J Natl Compr Canc Netw. 2015 Mar;13(3):252-4. No abstract available.

25.

Treatment-related toxicities in older adults with head and neck cancer: A population-based analysis.

O'Neill CB, Baxi SS, Atoria CL, O'Neill JP, Henman MC, Sherman EJ, Lee NY, Pfister DG, Elkin EB.

Cancer. 2015 Jun 15;121(12):2083-9. doi: 10.1002/cncr.29262. Epub 2015 Feb 27.

26.

Trends in chemoradiation use in elderly patients with head and neck cancer: Changing treatment patterns with cetuximab.

Baxi SS, O'Neill C, Sherman EJ, Atoria CL, Lee NY, Pfister DG, Elkin EB.

Head Neck. 2016 Apr;38 Suppl 1:E165-71. doi: 10.1002/hed.23961. Epub 2015 Jun 26.

27.

Head and neck cancers, Version 2.2014. Clinical practice guidelines in oncology.

Pfister DG, Spencer S, Brizel DM, Burtness B, Busse PM, Caudell JJ, Cmelak AJ, Colevas AD, Dunphy F, Eisele DW, Gilbert J, Gillison ML, Haddad RI, Haughey BH, Hicks WL Jr, Hitchcock YJ, Jimeno A, Kies MS, Lydiatt WM, Maghami E, Martins R, McCaffrey T, Mell LK, Mittal BB, Pinto HA, Ridge JA, Rodriguez CP, Samant S, Schuller DE, Shah JP, Weber RS, Wolf GT, Worden F, Yom SS, McMillian NR, Hughes M; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2014 Oct;12(10):1454-87.

28.

New chapter in our understanding of human papillomavirus-related head and neck cancer.

Pfister DG, Fury MG.

J Clin Oncol. 2014 Oct 20;32(30):3349-52. doi: 10.1200/JCO.2014.56.5754. Epub 2014 Sep 15. No abstract available.

PMID:
25225434
29.

Efficacy of concurrent cetuximab vs. 5-fluorouracil/carboplatin or high-dose cisplatin with intensity-modulated radiation therapy (IMRT) for locally-advanced head and neck cancer (LAHNSCC).

Shapiro LQ, Sherman EJ, Riaz N, Setton J, Koutcher L, Zhang Z, Shi W, Fury MG, Wolden SL, Pfister DG, Morris L, Lee N.

Oral Oncol. 2014 Oct;50(10):947-55. doi: 10.1016/j.oraloncology.2014.07.001. Epub 2014 Aug 11.

30.

Causes of death in long-term survivors of head and neck cancer.

Baxi SS, Pinheiro LC, Patil SM, Pfister DG, Oeffinger KC, Elkin EB.

Cancer. 2014 May 15;120(10):1507-13. doi: 10.1002/cncr.28588. Epub 2014 Feb 22.

31.

Value considerations in the treatment of head and neck cancer: radiation, chemotherapy, and supportive care.

Baxi SS, Sher DJ, Pfister DG.

Am Soc Clin Oncol Educ Book. 2014:e296-303. doi: 10.14694/EdBook_AM.2014.34.e296. Review.

32.

Reply to J.E. Battley et al.

Pfister DG, Baxi SS.

J Clin Oncol. 2014 Apr 1;32(10):1092-3. doi: 10.1200/JCO.2013.54.3017. Epub 2014 Mar 3. No abstract available.

PMID:
24590648
33.

A phase II study of pralatrexate with vitamin B12 and folic acid supplementation for previously treated recurrent and/or metastatic head and neck squamous cell cancer.

Ho AL, Lipson BL, Sherman EJ, Xiao H, Fury MG, Apollo A, Seetharamu N, Sima CS, Haque S, Lyo JK, Sales R, Cox L, Pfister DG.

Invest New Drugs. 2014 Jun;32(3):549-54. doi: 10.1007/s10637-014-0073-x. Epub 2014 Feb 25.

PMID:
24566705
34.

Impact of obesity on the survival of patients with early-stage squamous cell carcinoma of the oral tongue.

Iyengar NM, Kochhar A, Morris PG, Morris LG, Zhou XK, Ghossein RA, Pino A, Fury MG, Pfister DG, Patel SG, Boyle JO, Hudis CA, Dannenberg AJ.

Cancer. 2014 Apr 1;120(7):983-91. doi: 10.1002/cncr.28532. Epub 2014 Jan 21.

35.

A phase 1 study of everolimus + weekly cisplatin + intensity modulated radiation therapy in head-and-neck cancer.

Fury MG, Lee NY, Sherman E, Ho AL, Rao S, Heguy A, Shen R, Korte S, Lisa D, Ganly I, Patel S, Wong RJ, Shaha A, Shah J, Haque S, Katabi N, Pfister DG.

Int J Radiat Oncol Biol Phys. 2013 Nov 1;87(3):479-86. doi: 10.1016/j.ijrobp.2013.06.2043.

PMID:
24074921
36.

The just price of cancer drugs and the growing cost of cancer care: oncologists need to be part of the solution.

Pfister DG.

J Clin Oncol. 2013 Oct 1;31(28):3487-9. doi: 10.1200/JCO.2013.50.3466. Epub 2013 Sep 3. No abstract available.

PMID:
24002517
37.

Head and neck cancers, version 2.2013. Featured updates to the NCCN guidelines.

Pfister DG, Ang KK, Brizel DM, Burtness BA, Busse PM, Caudell JJ, Cmelak AJ, Colevas AD, Dunphy F, Eisele DW, Gilbert J, Gillison ML, Haddad RI, Haughey BH, Hicks WL Jr, Hitchcock YJ, Kies MS, Lydiatt WM, Maghami E, Martins R, McCaffrey T, Mittal BB, Pinto HA, Ridge JA, Samant S, Schuller DE, Shah JP, Spencer S, Weber RS, Wolf GT, Worden F, Yom SS, McMillian NR, Hughes M; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2013 Aug;11(8):917-23. Erratum in: J Natl Compr Canc Netw. 2013 Dec 1;11(12):1458.

PMID:
23946171
38.

Long-term regional control in the observed neck following definitive chemoradiation for node-positive oropharyngeal squamous cell cancer.

Goenka A, Morris LG, Rao SS, Wolden SL, Wong RJ, Kraus DH, Ohri N, Setton J, Lok BH, Riaz N, Mychalczak BR, Schoder H, Ganly I, Shah JP, Pfister DG, Zelefsky MJ, Lee NY.

Int J Cancer. 2013 Sep 1;133(5):1214-21. doi: 10.1002/ijc.28120. Epub 2013 Mar 29.

39.

A phase 1 study of everolimus plus docetaxel plus cisplatin as induction chemotherapy for patients with locally and/or regionally advanced head and neck cancer.

Fury MG, Sherman E, Ho AL, Xiao H, Tsai F, Nwankwo O, Sima C, Heguy A, Katabi N, Haque S, Pfister DG.

Cancer. 2013 May 15;119(10):1823-31. doi: 10.1002/cncr.27986. Epub 2013 Feb 13.

40.

Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer.

Ho AL, Grewal RK, Leboeuf R, Sherman EJ, Pfister DG, Deandreis D, Pentlow KS, Zanzonico PB, Haque S, Gavane S, Ghossein RA, Ricarte-Filho JC, Domínguez JM, Shen R, Tuttle RM, Larson SM, Fagin JA.

N Engl J Med. 2013 Feb 14;368(7):623-32. doi: 10.1056/NEJMoa1209288.

41.

Evaluation of romidepsin for clinical activity and radioactive iodine reuptake in radioactive iodine-refractory thyroid carcinoma.

Sherman EJ, Su YB, Lyall A, Schöder H, Fury MG, Ghossein RA, Haque S, Lisa D, Shaha AR, Tuttle RM, Pfister DG.

Thyroid. 2013 May;23(5):593-9. doi: 10.1089/thy.2012.0393.

42.

Sharing a diagnosis of HPV-related head and neck cancer: the emotions, the confusion, and what patients want to know.

Baxi SS, Shuman AG, Corner GW, Shuk E, Sherman EJ, Elkin EB, Hay JL, Pfister DG.

Head Neck. 2013 Nov;35(11):1534-41. doi: 10.1002/hed.23182. Epub 2012 Nov 20.

43.

A randomized phase II study of cetuximab every 2 weeks at either 500 or 750 mg/m2 for patients with recurrent or metastatic head and neck squamous cell cancer.

Fury MG, Sherman E, Lisa D, Agarwal N, Algazy K, Brockstein B, Langer C, Lim D, Mehra R, Rajan SK, Korte S, Lipson B, Yunus F, Tanvetyanon T, Smith-Marrone S, Ng K, Xiao H, Haque S, Pfister DG.

J Natl Compr Canc Netw. 2012 Nov 1;10(11):1391-8.

44.

Ten years of progress in head and neck cancers.

Baxi S, Fury M, Ganly I, Rao S, Pfister DG.

J Natl Compr Canc Netw. 2012 Jul 1;10(7):806-10. No abstract available.

45.

Molecular-targeted therapies in head and neck cancer.

Rao SD, Fury MG, Pfister DG.

Semin Radiat Oncol. 2012 Jul;22(3):207-13. doi: 10.1016/j.semradonc.2012.03.005.

PMID:
22687945
46.

A phase I study of temsirolimus plus carboplatin plus paclitaxel for patients with recurrent or metastatic (R/M) head and neck squamous cell cancer (HNSCC).

Fury MG, Sherman E, Ho A, Katabi N, Sima C, Kelly KW, Nwankwo O, Haque S, Pfister DG.

Cancer Chemother Pharmacol. 2012 Jul;70(1):121-8. doi: 10.1007/s00280-012-1894-y. Epub 2012 May 27.

PMID:
22644799
47.

Hemorrhagic pseudoaneurysm in a patient receiving aflibercept for metastatic thyroid cancer.

Baxi SS, Sherman EJ, Kelly KW, Brown KT, Dematteo RP, Pfister DG.

Thyroid. 2012 May;22(5):552-5. doi: 10.1089/thy.2011.0413. Epub 2012 Apr 17.

48.

A phase 2 study of bevacizumab with cisplatin plus intensity-modulated radiation therapy for stage III/IVB head and neck squamous cell cancer.

Fury MG, Lee NY, Sherman E, Lisa D, Kelly K, Lipson B, Carlson D, Stambuk H, Haque S, Shen R, Kraus D, Shah J, Pfister DG.

Cancer. 2012 Oct 15;118(20):5008-14. doi: 10.1002/cncr.27498. Epub 2012 Mar 13.

49.

Mucosal melanoma of the head and neck.

Pfister DG, Ang KK, Brizel DM, Burtness B, Cmelak AJ, Colevas AD, Dunphy F, Eisele DW, Gilbert J, Gillison ML, Haddad RI, Haughey BH, Hicks WL Jr, Hitchcock YJ, Kies MS, Lydiatt WM, Maghami E, Martins R, McCaffrey T, Mittal BB, Pinto HA, Ridge JA, Samant S, Sanguineti G, Schuller DE, Shah JP, Spencer S, Trotti A 3rd, Weber RS, Wolf G, Worden F; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2012 Mar;10(3):320-38. No abstract available.

PMID:
22393194
50.

TALK score: Development and validation of a prognostic model for predicting larynx preservation outcome.

Sherman EJ, Fisher SG, Kraus DH, Zelefsky MJ, Seshan VE, Singh B, Shaha AR, Shah JP, Wolf GT, Pfister DG.

Laryngoscope. 2012 May;122(5):1043-50. doi: 10.1002/lary.23220. Epub 2012 Feb 28.

Supplemental Content

Loading ...
Support Center